Senti Biosciences (SNTI) Retained Earnings (2021 - 2025)
Senti Biosciences' quarterly Retained Earnings came in at -$358.6 million in Q4 2025, down 20.69% year-on-year from -$452.1 million in Q4 2024, and down 4.21% quarter-over-quarter from -$344.1 million in Q3 2025.
Senti Biosciences has reported Retained Earnings for 5 years, with the latest figure at -$358.6 million in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 20.69% year-over-year to -$358.6 million; the trailing twelve-month figure through Dec 2025 stood at -$358.6 million (down 20.69% YoY), and the FY2025 full-year result was -$358.6 million, down 20.69% from the prior year.
- Retained Earnings for Q4 2025 stood at -$358.6 million, down from -$344.1 million in the prior quarter.
- The five-year high for Retained Earnings was -$1178.0 in Q1 2021, with the low at -$358.6 million in Q4 2025.
- Average Retained Earnings over 5 years is -$194.4 million, with a median of -$218.2 million recorded in 2023.
- Year-over-year, Retained Earnings tumbled 864587.1% in 2022 and fell 16.06% in 2025.
- Tracing SNTI's Retained Earnings over 5 years: stood at -$115.1 million in 2021, then plunged by 50.55% to -$173.3 million in 2022, then tumbled by 41.01% to -$244.3 million in 2023, then dropped by 21.6% to -$297.1 million in 2024, then decreased by 20.69% to -$358.6 million in 2025.
- The last three Retained Earnings figures came in at -$358.6 million (Q4 2025), -$344.1 million (Q3 2025), and -$326.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -358.60 Mn |
| Sep 30, 2025 | -344.11 Mn |
| Jun 30, 2025 | -326.00 Mn |
| Mar 31, 2025 | -311.25 Mn |
| Dec 31, 2024 | -297.13 Mn |
| Sep 30, 2024 | -296.50 Mn |
| Jun 30, 2024 | -267.66 Mn |
| Mar 31, 2024 | -256.46 Mn |
| Dec 31, 2023 | -244.34 Mn |
| Mar 31, 2023 | -192.00 Mn |
| Dec 31, 2022 | -173.29 Mn |
| Sep 30, 2022 | -155.08 Mn |
| Jun 30, 2022 | -138.44 Mn |
| Mar 31, 2022 | -10.19 Mn |
| Dec 31, 2021 | -115.10 Mn |
| Sep 30, 2021 | -6.52 Mn |
| Jun 30, 2021 | -6.23 Mn |
| Mar 31, 2021 | -1,178.00 |